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Abstract
Background Often ignored, hands are one of the most
telltale signs of aging. This prospective study was initiated
to evaluate the effect of subcutaneous hyaluronic acid (HA)
injections in aging hands, with special attention to com-
plications and long-term outcomes.
Methods Between January 2010 and December 2010, a
total of 38 patients with skin phototypes II–IV and between
58 and 76 years old were treated with HA injection for
aging hands. The quantity of injection never exceeded
1.0–1.5 ml HA per hand. A clinical follow-up was per-
formed at 2 weeks, 4 weeks, 3 months, and 6 months after
injection. Complications were reviewed for the whole
series. At the first follow-up, 2 weeks after the procedure,
ultrasound was carried out to determine if additional filling
material was required. At each follow-up, patients were
asked to fill out a satisfaction questionnaire.
Results Nine patients developed slight ecchymosis that
disappeared after 1 week. No other complications were seen
in the series. Pain during the injection and discomfort after
the procedure were minimal. At the 2-week follow-up, after
ultrasound control, nine patients received a complementary
injection. At each follow-up, overall patient satisfaction was
high and was validated by clearance of rhytids, veins, bony
prominences, and dermal and subcutaneous atrophy.
Conclusion Skin revitalization with injectable HA can
improve the clinical appearance of the back of the hands.
However, this therapy requires knowledge of the possible
complications and their remediation as well as knowledge and
respect of injected doses. Moreover, despite excellent results
at each follow-up, the results of our series are not as good
after 6 months, and a longer follow-up would be needed to
determine if this procedure provides long-lasting benefit.
Level of Evidence III This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
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The face is frequently the focus of rejuvenation [1–5].
Often ignored, hands exhibit some of the most telltale signs
of aging. Clinically, photoaging or extrinsic aging must be
distinguished from intrinsic aging [6]. Intrinsically aging
hands are characterized by rhytids, dermal and fat atrophy,
visible color of tendons, prominent veins, and noticeable
bony contours [7]. In the field of hand rejuvenation, ther-
apies have focused mainly on reducing pigmentation
through laser irradiation, intense pulsed light, chemical
peels, and microabrasions [8]. Studies on corrections of the
intrinsic aspects of aging hands are still limited and often
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involve autologous fat injections, sclerotherapy, phlebec-
tomy, or skin excision [9, 10].
Hyaluronic acid (HA) is a linear polysaccharide com-
prising alternating glucuronic acid and N-acetylglucosam-
ines residues and belongs to a group of substances known as
glycosaminoglycans. Skin normally contains the highest
concentration of hyaluronic acid within the body. However,
with time, there is a progressive depletion of endogenous
HA [11]. HA has been implicated in a number of processes
during early wound healing, including cell migration and
proliferation [12], organization of granulation tissue, stim-
ulating angiogenesis, and moderating the inflammatory
response [12, 13]. After modification of HA into a more
stabilized preparation, these properties have been used
successfully by dermatologists and plastic surgeons in facial
rejuvenation for restoring skin volume and improving its
physiology. Its typical effects can last up to 9 months
depending on the treated area. Despite the numerous studies
evaluating this therapy on the face [1–5], there is still a
paucity of studies [14, 15] describing its potential on hand
rejuvenation. This prospective study was initiated to eval-
uate the effect of subcutaneous HA injections in aging
hands, with special attention paid to complications, patient
satisfaction, and outcomes, i.e., clearance of rhytids, veins,
bony prominences, and dermal and subcutaneous atrophy.
Materials and Methods
Patients
This clinical study protocol was reviewed and approved by
the Ethics Committee of our institution. Thirty-eight
patients with skin phototypes II–IV and between 58 and
76 years old (average = 69 ± 4 years) were enrolled.
They signed an informed consent form for the study and
injection after having been informed of all pertinent details.
Filler
A HA-based filler of nonanimal origin (Cristal 2, DP Italia,
Italy, and Irradia, Spain) was injected for hand rejuvena-
tion. The molecular size of this HA is 300 lm and it has a
viscosity of 20,000 mPa s. The filler is composed of
24 mg/ml sodium hyaluronate cross-linked hyaline gel
type. One important characteristic of this HA is that
although it has large molecules, it also has thixotropic
properties that enable its injection with a 27G cannula. This
is not possible with standard high-viscosity HAs because
high viscosity directly impacts the resistance of the fluid
and its ability to pass through a small-diameter cannula. In
the case of the particular product used in this study, vis-
cosity was changed by shear stress or pressure applied
tangentially to the HA contained in the syringe. The HA
gel product becomes thinner when stressed by the pressure
placed on the syringe at the time of the injection, causing it
to pass with ease through the needle for precise deposition
into the tissue. Due to the thixotropic property of the HA, it
takes a fixed amount of time to transform into a firmer,
more solid viscous equilibrium once it is introduced into
the skin and reaches dermal layers. During this time,
pressure is applied using a maneuver in which the injection
molds the product in the area, easily obtaining the desired
shape. There is usually no need to inject more than
1.0–1.5 ml of HA per hand. In cases of significant skin
laxity and fat atrophy, another injection is given after
2 weeks to achieve optimal filling. This allows for accurate
control of the amount of HA needed and avoids the typical
aspect of dorsum edema after treatment.
Injection Technique
Once anesthesia (2 % lidocaine) is injected at the point
where the cannula is to be introduced, a 21G needle is used
to pierce the skin in the fold that appears when the hand is
hyperextended. This cannula entry point permits easy
access to the spaces between the tendons (Fig. 1). If the
depression is more distal, then needle access is between the
second and third and between the third and fourth fingers.
In these instances, a 27G blunt and flexible cannula
(40 mm long), with a lateral opening to allow the filler out,
is introduced. To avoid damaging the synovial layers of the
tendon, the skin is pinched with the thumb and index fin-
gers. This is easy to do because of the laxity presented by
aged hands. Once the cannula is inserted between the fin-
gers and the correct area is selected, it is moved in a gentle
longitudinal swinglike motion, avoiding lateral side-to-side
movement so as not to damage the superficial nerves. The
flexibility of the cannula causes it to bend easily and
therefore help in the maneuver. Also, its length makes it
possible to reach the various distances of the hand dorsum.
Postoperative Care
Patients were advised to avoid strenuous hand activity and
not let the hands hang down for too long as the effects of
gravity would cause painful and uncomfortable edema on
the back of the hands. Patients received 15 mg of pred-
nisolone immediately after treatment and 24 h later.
Objective Assessment
At the 2-week, 4-week, 3-month, and 6-month follow-up,
clinical examination was performed and complications
were carefully recorded, with special attention given to
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persistent ecchymosis, edema, pain, hyperpigmentation,
and prolonged alterations in sensitivity. During each fol-
low-up the patients were evaluated independently by three
surgeons: two plastic surgeons and a vascular surgeon in
the same clinic. Aging aspects were assessed using the
following criteria: clearance of rhytids, veins, bony prom-
inences, and clearance of dermal and subcutaneous atro-
phy. Using a visual scale, each criterion was then scored by
the three evaluators, who did not consult among them-
selves, and the surgeon who performed the procedure.
Results were ranked as excellent: 90–100 % clearance,
good: 70–89 % clearance, regular: 40–69 % clearance, and
poor: 0–39 % clearance. At the end of the consultation, the
results were collected and shared and a final mean was
calculated for each patient. At the first follow-up 2 weeks
after the procedure, ultrasound (SonoSit MicroMAxx,
SOnoSIte Inc., USA with transducer L38, 10–5 MHz) was
carried out. The ultrasound criteria used to determine that
there was insufficient filling were inhomogeneous distri-
bution of the HA in the intermetacarpal space or non-
symmetrical filling compared to the contralateral side.
Ultrasound confirmed the residual skin laxity and fat
atrophy and the injection was repeated in the incompletely
filled area to achieve optimal results. Ultrasound confir-
mation permitted precise injection of the amount of HA
needed and avoided the typical aspect of dorsum edema
after treatment.
Subjective Assessment
Patients were asked to rate their level of discomfort while
the hands were anesthetized and after the procedure using
the questionnaire shown in Table 1. The answers were
given a numerical score, where 0, no pain/tingling/bruis-
ing/discomfort; 1, slight pain/tingling/bruising/discomfort;
2, moderate pain/tingling/bruising/discomfort; 3, severe
pain/tingling/bruising/discomfort; and 4, very severe pain/
tingling/bruising/discomfort. Inability to work was care-
fully recorded (0 = nil, 1 = one day, 2 = two days,
3 = three days, 4 = more than 3 days). Patients were
asked to score their improvement at each follow-up period
(from 0 to 100 %) on a visual scale [Expectations met: 4
(excellent) = 90–100 %; 3 (good) = 70–89 %; 2 (regu-
lar) = 40–69 %; 1 (poor) = 0–39 %]. At the 6 month
follow-up, patients were asked whether they would rec-
ommend the procedures to others.
Statistical Analysis
The prospective study included 38 patients with aging
hands compared prior to and 2 weeks, 4 weeks, 3 months,
and 6 months after HA injection. The different measure-
ments are reported in Tables 2, 3, 4. An ANOVA with main
variables of time and the individual patient was performed
to show differences between the four postinjection points
(patient effects were isolated). The following parameters
were scored: clearance of rhytids, veins, bony prominences,
and dermal and subcutaneous atrophy. A p \ 0.05 was
considered to be statistically significant. Student’s t test
(two dependent samples) was subsequently used to show
differences between the measurements 2 weeks after HA
injection and each of the latter time points for each
parameter. Statistical analysis was performed using the
SPSS Stat program (SPSS, Inc., Chicago, IL).
Fig. 1 a Control of the cannula
in the space noticed between the
tendons. b HA injection using
gentle longitudinal swing-like
movements
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Table 1 Questionnaire used for
our study
Did you experience pain, tingling, or bruising during the injection?
h NO
h YES:
Pain: h Slight h Moderate h Severe h Very severe
Tingling: h Slight h Moderate h Severe h Very severe
Bruising: h Slight h Moderate h Severe h Very severe
Did you feel discomfort immediately after the procedure and during the first two weeks?
h NO
h YES:
h Slight h Moderate h Severe h Very severe
Has the procedure interfered with your daily activities?
h NO
h YES:
h Slight h Moderate h Severe h Very severe
Has the procedure prevented you from working?
h NO
h YES:
h 1 day h 2 days h 3 days h[ 3 days
How do you perceive the improvement brought by the procedure?
(please mark it on the visual scale)
2 weeks 0 % ? 100 % (excellent)
1 month 0 % ? 100 % (excellent)
3 months 0 % ? 100 % (excellent)
6 months 0 % ? 100 % (excellent)
Would you recommend this treatment to others?
h YES
h NO
Table 2 Complaints during
the injection, discomfort after
the procedure, and interference
with daily activities in our
series of 38 patients
During injection During the first 2 weeks Interference with daily activities
Pain Tingling Bruising Discomfort
0: No 35 37 34 36 36
1: Slight 2 1 4 2 2
2: Moderate 1 0 0 0 0
3: Severe 0 0 0 0 0
4: Very severe 0 0 0 0 0
Table 3 Subjective
improvement in our series of
38 patients
Efficacy % Score 2 weeks 1 month 3 months 6 months
Excellent 90–100 4 33 32 31 26
Good 70–89 3 3 4 4 7
Regular 40–69 2 2 2 3 5
Poor 10–39 1 0 0 0 0
Mean ± SD (p) 3.8 ± 0.5 3.8 ± 0.5 (0.16) 3.7 ± 0.6 (0.08) 3.5 ± 0.7 (\ 0.01)




Except mild ecchymosis in 9 patients that resolved within
1 week, there were no complications in our series (Figs. 2,
3, 4, 5).
Subjective Assessment
The incidence of pain, tingling, and bruising during the
procedure is reported in Table 2. Slight discomfort post
procedure was reported by two patients. Return to normal
activities never took longer than 1 day and mean downtime
was 0.1 day. Mean subjective improvement at 2 weeks,
1 month, 3 months, and 6 months (Table 3) was 3.8 ± 0.5,
3.8 ± 0.5 (p = 0.16), 3.7 ± 0.6 (p = 0.08), and 3.5 ± 0.7
(p \ 0.01), respectively. Of the 38 patients, 29 would
recommend this treatment. The remaining 9 patients stated
they would not recommend this procedure because they
experienced unexpected ecchymosis (Figs. 6, 7).
Ultrasound Assessment
At the 2 week follow-up, ultrasound revealed insufficient
filling in the fold of the second intermetacarpal space for
Table 4 Effect of the therapy on rhytids, veins, bony prominences, and dermal and subcutaneous atrophy
Efficacy % Score 2 weeks 1 month 3 months 6 months
Clearance of rhytids Excellent 90–100 4 29 32 27 23
Good 70–89 3 5 3 7 9
Regular 40–69 2 4 3 4 6
Poor 10–39 1 0 0 0 0
Mean ± SD (p) 3.7 ± 0.6 3.7 ± 0.5 (0.02) 3.6 ± 0.7 (0.006) 3.4 ± 0.8 (0.006)
Clearance of veins Excellent 90–100 4 31 34 28 24
Good 70–89 3 4 3 5 9
Regular 40–69 2 3 1 5 5
Poor 10–39 1 0 0 0
Mean ± SD (p) 3.7 ± 0.6 3.9 ± 0.4 (0.01) 3.6 ± 0.7 (0.001) 3.5 ± 0.7 (0.02)
Clearance of bony prominences Excellent 90–100 4 31 30 29 26
Good 70–89 3 4 6 6 8
Regular 40–69 2 3 2 3 3
Poor 10–39 1 0 0 0 1
Mean ± SD (p) 3.7 ± 0.6 3.7 ± 0.6 (0.5) 3.7 ± 0.6 (0.08) 3.6 ± 0.7 (0.02)
Dermal and subcutaneous atrophy Excellent 90–100 4 27 31 26 22
Good 70–89 3 7 4 5 9
Regular 40–69 2 4 3 6 5
Poor 10–39 1 0 0 1 2
Mean ± SD (p) 3.6 ± 0.7 3.7 ± 0.6 (0.01) 3.5 ± 0.9 (\ 0.001) 3.3 ± 0.9 (0.01)
Fig. 2 59-year-old patient
before (a) and 6 months after
HA injection (b)
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one patient, in the fold of the second and third intermeta-
carpal spaces for seven patients, and in the fold of the
fourth intermetacarpal space for one patient. These nine
patients received a complementary injection because of
insufficient results after the first treatment. For the nine
patients who were reinjected, the follow-up began at the
time of the second injection.
Objective Assessment
The mean scores at 2 weeks, 1 month, 3 months, and
6 months (Table 4) were 3.7 ± 0.6, 3.7 ± 0.5, 3.6 ± 0.7,
and 3.4 ± 0.8, respectively, for clearance of rhytids. The
ANOVA shows significant differences (p \ 0.001) in
scores between the different points in time for this
Fig. 3 66-year-old patient
before (a) and 6 months after
HA injection (b)
Fig. 4 58-year-old patient
before (a) and 6 months after
HA injection (b)
Fig. 5 76-year-old patient
before (a) and 6 months after
HA injection (b)
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parameter. The p values for the paired t tests were 2 weeks
versus 1 month: 0.044, 2 weeks versus 3 months: 0.160,
and 2 weeks versus 6 months: 0.003.
Mean subjective scores at 2 weeks, 1 months, 3 months,
and 6 months (Table 4) were 3.7 ± 0.6, 3.9 ± 0.4,
3.6 ± 0.7, and 3.5 ± 0.7, respectively, for clearance of
veins. The ANOVA shows significant differences
(p \ 0.001) in scores between the different points in time
for clearance of veins. The p values for the paired t tests
were 2 weeks versus 1 month: 0.023, 2 weeks versus
3 months: 0.023, and 2 weeks versus 6 months: 0.002.
Mean subjective scores at 2 weeks, 1 months, 3 months,
and 6 months (Table 4) were 3.7 ± 0.6, 3.7 ± 0.6,
3.7 ± 0.6, and 3.6 ± 0.7, respectively, for clearance of
bony prominences. The ANOVA analysis shows significant
differences (p = 0.001) in scores between the different
points in time for this parameter. The p values for the
paired t tests were 2 weeks versus 1 month: 1.000, 2 weeks
versus 3 months: 0.160, and 2 weeks versus 6 months:
0.006.
Mean subjective scores at 2 weeks, 1 months, 3 months,
and 6 months (Table 4) were 3.6 ± 0.7, 3.7 ± 0.6,
3.5 ± 0.9, and 3.3 ± 0.9, respectively, for clearance of
dermal and subcutaneous atrophy. The ANOVA shows
significant differences (p \ 0.001) in scores between the
different points in time for this parameter. The p values for
the paired t tests were 2 weeks versus 1 month: 0.023,
2 weeks versus 3 months: 0.023, and 2 weeks versus
6 months: 0.001.
Discussion
Often neglected by plastic surgeons, hands exhibit the most
telltale signs of aging. Resurgence in the treatment of aging
hands, in both the aesthetics of the hand and volumetric
options for intrinsic aging, is occurring due to (1) patient
demand; (2) the current literature on face rejuvenation
[1–5], and (3) the creation of dedicated societies like the
Multidisciplinary European Group for Aesthetics of the
Hand (MEGAHAND). However, most of the therapies
have concentrated on keratosis, solar lentigo, solar purpura,
and rhytids. These therapies include sclerotherapy, intense
pulsed light, laser, and microdermabrasion [8, 14]. Unfor-
tunately, the results are unpredictable and only temporary.
Hypertrophic scarring, hyperpigmentation, and dyschromia
are known complications of these therapies, especially in
darker-skinned patients [6].
Because aging hands are more complex and include not
only rhytids and skin appearance but also dermal and fat
atrophy and veins and bony prominences, a different
approach is required. Studies on the restoration of a more
youthful fullness of the hands that focus on all of these
characteristics are still limited and often involve skin
excision, sclerotherapy, phlebectomy, and autologous fat
injections. Excision and redraping of lax skin recreates a
tight, youthful skin envelope, increasing the visibility of
the underlying structures and thus exaggerating the initial
problem of soft tissue loss [6, 16]. Sclerotherapy and
phlebectomy may temporarily reduce visible veins, but due
Fig. 6 Mild ecchymosis occurring after HA injection at the level of
the fourth intermetacarpal space
Fig. 7 Mild ecchymosis occurring after HA injection at the level of
the second and third intermetacarpal spaces
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to impairment of venous return, edema formation and
venous stasis may affect the patient permanently [6].
Because the hand lacks efficient deep venous drainage, the
remaining veins will likely engorge over time. Fat injec-
tions to augment low-volume areas and soften the outline
of deeper structures seem to be very promising [6, 9, 10,
16, 17]; however, since this is invasive therapy, it has led to
some teams testing other fillers such as collagen or hyal-
uronic acid [15].
Hyaluronic acid is a glycosaminoglycan found in epi-
thelial and connective tissue. HA has been implicated in a
number of processes during early wound healing, including
cell migration and proliferation [12], organization of
granulation tissue, stimulation of angiogenesis, and mod-
eration of the inflammatory response [13]. In the field of
hand rejuvenation, the effectiveness of HA is based on its
biocompatibility and its viscoelastic properties. However,
due to its half-life of 1–2 days before enzymatic degrada-
tion, a chemical reticulation is necessary to obtain a water-
insoluble viscoelastic polymer with improved resistance to
enzymatic reaction [14]. Our results after injection of
nonanimal stabilized HA in the dorsum of the hands have
shown significant clearance of rhytids, veins, bony prom-
inences, and dermal and subcutaneous atrophy for all
periods of observation. These results are partly explained
by the fact that HA is able to hold up to 500–1,000 times its
own weight of water in the extracellular matrix of the
dermis [18]. In this context, Williams et al. [14], using a
suction elasticity meter and moisture-measuring device,
have clearly demonstrated an increase in cutaneous elas-
ticity and stratum corneum hydration after stabilized HA
injection in the dorsum of the hand. Their studies con-
firmed the previous report from Kerscher et al. [19] who
used nonanimal stabilized HA for revitalization of the face,
with excellent results for volume restoration, skin elastic-
ity, and reduction in skin surface roughness. Moreover,
Yoneda et al. [20], in an animal model, highlighted that
exogenous stabilized HA acts as a modulator of dermal
fibroblast proliferation that modifies indirectly the synthe-
sis of collagen. Finally, Wang et al. [21] demonstrated that
nonanimal stabilized HA injected into the dermal matrix is
able to enhance the stimulation of de novo synthesis of type
I collagen, possibly mediated by mechanical stretching and
consequent activation of collagen-producing fibroblasts in
the dermis.
Our results on the clearance of rhytids, veins, bony
prominences, and dermal and subcutaneous atrophy are
corroborated by the extremely high satisfaction of patients
for each period of observation: they considered the results
good to excellent in about 87 % (6 months) to 92 %
(3 months) of cases, depending on the follow-up period.
Moreover, 71 % of them would recommend this therapy to
others. The remaining nine patients (29 %) declared that
they would not recommend this therapy because they
experienced ecchymosis for which they were not prepared.
This shows the consequences of even minor complications
in highly demanding patients. Finally, complaints experi-
enced during the injection phase are minimal in this study.
Such subjective data, particularly the analysis of pain
during injection, until now have not been reported in the
literature [14].
In our study, in addition to the excellent results and
the high satisfaction of the patients, there are very few
complications. Complications included five instances of
ecchymosis, which resolved after 10 days, and no patient’s
ability to work was hampered as the average down time
was less than 1 day. Even though there were only a few
complications in our study, they must be kept in mind by
all operators [22]. There are indeed two types of exogenous
stabilized HA: that of animal origin obtained by extraction
and the nonanimal type that we used, obtained by fer-
mentation. The first type carries a risk of allergic reaction
related to the protein content, and the second can cause
immunological reactions related to the presence of endo-
toxin [23]. In our experience, knowledge of the product is
required but it is by no means enough in order to perform
these injections for the following reasons: the studies of
Lowe et al. [23], Brody et al. [24], and Lupton et al. [25]
showed the risk of hypersensitivity reaction related to the
use of these products. They must be handled by plastic
surgeons or dermatologists who understand the potential
complications and know how to manage them [26]. The use
of hyaluronidase, which is the first tool that acts at the site
of local injections to break down and hydrolyze hyaluronic
acid, should be familiar to the operator. Moreover,
knowledge and respect of doses is fundamental: In our
experience, there is usually no need to inject more than
1.0–1.5 ml of HA per hand. In cases of significant skin
laxity and fat atrophy, we repeated the injection after
2 weeks to achieve optimal filling. This allows for accurate
control of the amount of HA needed and avoids the typical
aspect of dorsum edema and ecchymosis after treatment.
Finally, frequent follow-ups are necessary to assess the
effectiveness of treatment and the possible occurrence of
complications. In our study, a statistically significant dif-
ference was found between the 3 month and the 6 month
follow-up regarding subjective improvement. This moni-
toring can also be used to repeat the injection if necessary.
Williams et al. [14] confirmed this by showing that the
injection should be repeated after 4 months. This frequency
rate is much higher than that found in the literature for
injections in the face, probably because of the different
physiology of the skin at the two locations, but also
because the hands are washed more frequently.
Although our study shows an improvement in aging
hands by injections of stabilized HA, it also presents
1374 Aesth Plast Surg (2012) 36:1367–1375
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methodological limitations. First, a control group is clearly
lacking. Because of our wealth of experience with the
nonanimal stabilized HA product and the lack of compli-
cations, we did not feel inclined to use another product.
Second, the follow-ups at 3 and 6 months appear too far
apart and more frequent follow-ups would have been
appropriate to determine precisely (as in the study of
Williams et al. [14]) the best time for reinjection. In this
context it is important to emphasize that the results at
6 months are not as good as those at 2 weeks after the
procedure, and a longer follow-up is needed to determine if
this procedure provides long-lasting benefit. Moreover, this
study focused on the restoration of volume and largely
omits the changes in skin physiology [15]. We preferred to
focus our efforts on the subjective evaluation of the
injection that has been largely neglected in the literature.
Finally, given the necessary repetition of this type of
treatment to maintain the rejuvenation, it would have been
interesting to evaluate the risk of complications after reg-
ular injections. A multicenter study is underway on a large
cohort of patients.
Conclusion
Skin revitalization with injectable HA can improve the
clinical appearance of the back of the hand. However, this
therapy necessitates knowledge of the possible complica-
tions and their treatments and knowledge and respect of
injected doses. Moreover, despite excellent results at each
follow-up, the results of our series are not as good after
6 months, and a longer follow-up would be needed to
determine if this procedure is of long-lasting benefit.
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